Biogen Target Raised to $305 as Q3 Swings to Loss Despite Revenue Growth
Piper Sandler lifted its price target on Biogen to $305. The move comes as third-quarter results showed higher revenue but an unexpected net loss.
Biogen Inc. has drawn fresh attention after Piper Sandler reiterated an Overweight rating on the stock and increased its price target from $245 to $305, representing an increase of 24.49%. The decision points to confidence in the drugmaker's pipeline focused on neurological and neurodegenerative disorders as it works to widen its commercial reach.
The updated view follows third-quarter 2026 financial results that produced contrasting trends. Revenue rose to US$2,804.1m from US$2,534.7m in the comparable prior period. However, a profit of US$466.5m shifted into a net loss of US$20.6m, driving the net margin down to -0.7%. Portfolio expansion has been supported by the completed US$5.3b acquisition of Apellis, which brought therapies EMPAVELI and SYFOVRE into Biogen's lineup.
Despite the quarterly loss, Biogen shares delivered a 58.9% return, including dividends, over the preceding twelve months, recently trading around US$248. A bearish narrative outlined on Simply Wall St suggested that the shares may already reflect the expected benefits of newer immunology, nephrology, and Alzheimer's assets, leaving vulnerability if clinical or regulatory execution falls short.
Valuation assessments continue to differ widely. GuruFocus reported a GF Value of $204.15 against a recent price of $257.44, describing the shares as 26.1% overvalued. GuruFocus also noted a trailing price-to-earnings ratio of 110.21x against a 5-year median of 17.18x, while calculating a financial strength rating of 6/10 and an overall GF Score of 74/100. GuruFocus added that 10 guru investors trimmed positions while two added to them, with no insider trades reported over three months.
Clinical milestones remain a primary focal point for market observers. Long-term phase II data from the ongoing AMETHYST trial evaluating litifilimab demonstrated sustained skin improvement through 52 weeks in cutaneous lupus erythematosus. Phase III data for the study are projected for the first half of 2027. Results for litifilimab in systemic lupus erythematosus are anticipated by the end of 2026, while phase III data for kidney therapy felzartamab are expected in 2027.